Table III.
Comparison among HAPE patients and two control groups.
| Group | n | NT-proBNP (pg/ml)1 | EPO (mU/ml)2 | VEGF (pg/ml)3 | NO (μmol/l)4 |
|---|---|---|---|---|---|
| HAPE patientsa | 21 | 110.33 (87.18, 147.84) | 59.25 (32.25, 327.00) | 108.21 (85.35, 129.68) | 25.00 (20.00, 50.00) |
| High-altitude controlb | 12 | 99.80 (85.47, 109.01) | 67.40 (48.25, 324.35) | 100.20 (74.66, 116.70) | 55.43 (46.77, 67.04) |
| Plain controlsc | 13 | 72.02 (57.83, 94.76) | 25.66 (10.65, 32.86) | 60.51 (46.54, 70.53) | 25.00 (12.50, 50.00) |
| P-value | 0.010 | 0.001 | 0.002 | 0.013 |
Results are medians (25th, 75th percentiles).
1:
a vs. b, P=0.309; a vs. c, P=0.002; b vs. c, P=0.019.
2:
a vs. b, P=0.637; a vs. c, P=0.002; b vs. c, P=0.001.
3:
a vs. b, P=0.308; a vs. c, P=0.007; b vs. c, P=0.001.
4:
a vs. b, P=0.005; a vs. c, P=0.559; b vs. c, P=0.030.
HAPE, high-altitude pulmonary edema; EPO, erythropoietin; VEGF, vascular endothelial growth factor; NT-proBNP, N-terminal probrain natriuretic peptide.